Which company develops and produces Duvelisib?

Duvelisib is developed and produced by Verastem Oncology. Verastem Oncology is a biopharmaceutical company focused on developing and commercializing innovative anti-cancer treatments. The company's mission is to provide more treatment options for cancer patients, especially those with rare cancer types or limited treatment options.

Verastem isVerastem One of the important research results of Oncology belongs to a class of drugs called PI3K inhibitors, which are used to treat specific types of lymphoma, such as adult T cell leukemia disease lymphoma/lymphoma cell leukemia (ATLL/CTCL) and relapsed smallB cell lymphoma. These diseases are usually related to abnormalities in the PI3K signaling pathway. Duveliside can interfere with this pathway, thereby slowing or inhibiting the growth of tumor cells.

Verastem Oncology is committed to bringing innovative treatments to market to improve survival and quality of life for cancer patients. They perform extensive work in drug development, clinical trials, and regulatory approvals to ensure the safety and effectiveness of their drugs. Duveliside is an important development of the company and provides new treatment options for patients suffering from certain types of lymphoma.

In short, duveliside is an anti-cancer drug developed and produced by Verastem Oncology and is used to treat certain types of lymphoma. This company focuses on the field of cancer treatment and strives to provide more treatment options to meet the needs of patients.

The original drug of Duvelisel Capsules has been launched in China, but it is not covered by medical insurance. Patients can buy it domestically at a price of more than 20,000 yuan. For specific prices, please consult the local hospital pharmacy.